Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
9.56
+0.03 (0.31%)
Feb 21, 2025, 4:00 PM EST - Market closed
Mineralys Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Mineralys Therapeutics stock have an average target of 27, with a low estimate of 24 and a high estimate of 30. The average target predicts an increase of 182.43% from the current stock price of 9.56.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Mineralys Therapeutics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $28 → $24 | Strong Buy | Maintains | $28 → $24 | +151.05% | Feb 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +213.81% | Feb 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +213.81% | Nov 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +213.81% | Oct 31, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +213.81% | Aug 15, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
8.50M
EPS This Year
-3.98
from -3.66
EPS Next Year
-3.68
from -3.98
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 43.7M | 160.3M | ||
| Avg | n/a | 8.5M | 90.1M | ||
| Low | n/a | n/a | 37.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,786.5% | ||
| Avg | - | - | 960.9% | ||
| Low | - | - | 343.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.73 | -3.26 | -3.34 | ||
| Avg | -3.98 | -3.68 | -3.84 | ||
| Low | -4.17 | -4.78 | -4.87 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.